Key statistics
On Thursday, Purple Biotech Ltd (PPBT:TLV) closed at 4.80, 2.13% above its 52-week low of 4.70, set on Nov 20, 2024.
52-week range
Open | 5.00 |
---|---|
High | 5.00 |
Low | 4.80 |
Bid | 4.80 |
Offer | 4.90 |
Previous close | 5.30 |
Average volume | 449.92k |
---|---|
Shares outstanding | 367.20m |
Free float | 366.13m |
P/E (TTM) | -- |
Market cap | 17.86m ILS |
EPS (TTM) | -0.2169 ILS |
Data delayed at least 20 minutes, as of Nov 21 2024 14:46 GMT.
More ▼
- Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death
- Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
- Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research
- Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
- Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
- Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
- Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
- Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
More ▼